Genzyme-backed program to chronicle lives of patients with MS

Share this article:
Genzyme-backed program to chronicle lives of patients with MS
Genzyme-backed program to chronicle lives of patients with MS
The lives of five patients with mutiple sclerosis will be chronicled online as part of a new program jointly developed by the National MS Society and Sanofi's Genzyme unit. The program, called Everyday Matters, chose the patients from a pool of 1,200 entries to receive individual support as they share experiences.

Organizers say they will seek to engage and inspire those living with or affected by MS by tapping into the field of positive psychology, drawing on the achievements of the patients to help inspire others. Patients will be tracked through a combination of personal text, video, and photo journals, all to be showcased on the website everydayMSmatters.org.

The patients -- who include a school teacher and single mom -- will focus on the top five aspects of life, as identified by MS patients in a June 2012 poll by the society: wellness, work/education, relationships, family and empowerment. Emmy-winning producer Kristen Adams, herself an individual living with MS, will help film the stories. A life coach who also has MS, Michelle Clos, will provide one-on-one coaching, and best-selling author of The Happiness Advantage, Shawn Achor, will guide efforts.

The site will also offer general resources, including toolkits that address the five core concerns highlighted in the MS society's survey.

“I know first-hand that ‘staying positive' can become that much more challenging after being diagnosed with a chronic and unpredictable disease like MS,” Clos said in a statement.

In June Genzyme submitted Lemtrada (alemtuzumab), for relapsing MS treatment, to the FDA and European regulators. An annual injection, the drug would compete against MS treatments like Novartis' Gilenya (fingolimod), Teva's Copaxone (glatiramer) and Biogen-Idec's Tysabri (natalizumab).

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...